Movement Alert｜Gilead Sciences Pre-Market Rise 3.7%, DZ Bank Raises Price Target to $191

Market Focus11-04 21:13

On November 4, Gilead Sciences rose 3.7% in Pre-Market Trading, trading at $173.65 per share, with turnover of $1.8687 million.

The clearest catalyst was a fresh target-price increase: DZ Bank lifted its price target on Gilead Sciences to $191 from $167, a level above the consensus target of $172.76, reinforcing bullish sentiment around the stock.

The move follows a broader string of supportive updates after Gilead Sciences reported third-quarter adjusted EPS of $2.55 on revenue of $8.30 billion, both above expectations, while raising full-year product sales guidance to $31.0 billion-$31.3 billion. Several firms had already raised their targets in recent days, including Bernstein to $175 and RBC to $131, providing additional context for the latest pre-market strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment